Значения термина secondary aml на английском

One of the nine relapsing patients developed secondary AML 18 months after transplant.

The response of secondary AML patients remains inferior.

Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics.

Methods: The estimated overall risk of secondary AML was calculated for the patient population as instances per 1000 patient-years of follow-up.

The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML.

In contrast, an epipodophyllotoxin was used in 12 of 13 previously reported patients who had secondary AML develop.

Conclusions: The authors concluded that the use of epipodophyllotoxins may be associated with an increased risk of having secondary AML develop in patients with ALL.

MK was found in 9.3% of patients and was more frequent in patients with advanced age or secondary AML.

These findings suggest that the cell of origin of secondary AML and ALL with 11q23 rearrangement is an immature haemopoietic progenitor cell.

We detected 2 cases of secondary AML and 1 case of MDS, 19, 52 and 12 months, respectively, after systemic chemotherapy for breast cancer.